QS Vulva

{ "short_title": "QS Vulva", "data_mode": "900", "data_mode_number": "000002366", "official_title": "Pelvic lymphadenectomy in vulvar cancer", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "adjuvant", "therapielinie_value": "first", "ctgov_number": null, "eudract_number": null, "general_contact_email": "studiensekretariat.gyn@ukdd.de", "general_contact_phone": "+49 351-4584202", "hauptpruefer_dd_name": "Prof. Dr. med. Pauline Wimberger", "description_laie_de": "Diese retrospektive, multizentrische Studie soll therapeutische Daten von allen Patienten sammeln, die \r\naufgrund eines VulvaCa in den Jahren 2017\u20132019 mittels eines chirurgischen Eingriffs behandelt wurden.", "description_laie_en": "This retrospective, multicenter study is designed to collect therapeutic data from all patients \r\ndiagnosed with primary inguino- femorally node- positive squamous cell vulvar cancer \r\n(VSCC) and treated with surgical staging of the groin/s in 2017-2019 at the gynaecological \r\ncancer centers participating in the AGO CaRE-1 Study.", "description_expert_de": "Diese retrospektive, multizentrische Studie soll therapeutische Daten von allen Patienten sammeln, die \r\naufgrund eines VulvaCa in den Jahren 2017\u20132019 mittels eines chirurgischen Eingriffs behandelt wurden", "description_expert_en": "This retrospective, multicenter study is designed to collect therapeutic data from all patients \r\ndiagnosed with primary inguino- femorally node- positive squamous cell vulvar cancer \r\n(VSCC) and treated with surgical staging of the groin/s in 2017-2019 at the gynaecological \r\ncancer centers participating in the AGO CaRE-1 Study.", "rechtsgrundlage_value": "BO", "phase_amg_value": null, "main_cat_id": 3, "sub_cat_id": 11 }